Details from two large trials of Novo Nordisk's GLP-1 drug semaglutide showed it provided no cognitive benefit for people with early Alzheimer's disease, researchers said at a medical meeting on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback